EUVIMEDEUVIMED entdecken
Open Access

Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis

Justin T Douglas, David K Johnson, Anuradha Roy, Taeju Park

Methods in Enzymology · 2024 · 301-342

DOI: 10.1016/bs.mie.2024.04.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Methods in Enzymology, 2024. Verfasst von Justin T Douglas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Magnetic Resonance Core Lab, University of Kansas, Lawrence, KS, United States. Hauptthemen laut MEDLINE: Crk-Associated Substrate Protein, src Homology Domains, Proto-Oncogene Proteins c-crk, Phosphotyrosine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCRR NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crk-Associated Substrate Proteinsrc Homology DomainsProto-Oncogene Proteins c-crkPhosphotyrosinePeptidesHumansProtein BindingAdaptor Proteins, Signal TransducingMolecular Docking SimulationNuclear Proteins

Stichwörter der Autor:innen

Computational dockingCrkCrkLP130CasPeptide ligandsPhosphotyrosineSH2 domains

Substanzen

Crk-Associated Substrate ProteinProto-Oncogene Proteins c-crkPhosphotyrosineCRKL proteinPeptidesBCAR1 protein, humanAdaptor Proteins, Signal TransducingCRK protein, humanNuclear Proteins

Autor:innen und Institutionen

  • Nuclear Magnetic Resonance Core Lab, University of Kansas, Lawrence, KS, United States.
  • Computational Chemical Biology Core, Molecular Graphics and Modeling Laboratory, University of Kansas, Lawrence, Kansas, United States.
  • High Throughput Screening Laboratory, University of Kansas, Lawrence, KS, United States.
  • Department of Pediatrics, Children's Mercy Kansas City and University of Missouri Kansas City School of Medicine, Kansas City, MO, United States.

Förderung

  • NIGMS NIH HHS
  • NCRR NIH HHS
  • NIH HHS
  • National Science Foundation
  • Cancer Center, University of Kansas
  • National Institutes of Health
  • National Institute of General Medical Sciences
  • Children's Mercy Hospital

Zitieren

APA

Douglas, J. T., Johnson, D. K., Roy, A., & Park, T. (2024). Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis. Methods in Enzymology, 301-342. https://doi.org/10.1016/bs.mie.2024.04.013

Vancouver

Douglas JT, Johnson DK, Roy A, Park T. Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis. Methods in Enzymology. 2024:301-342. doi:10.1016/bs.mie.2024.04.013

BibTeX
@article{Douglas2024,
  author = {Douglas, Justin T and Johnson, David K and Roy, Anuradha and Park, Taeju},
  title = {Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis},
  journal = {Methods in Enzymology},
  year = {2024},
  pages = {301--342},
  doi = {10.1016/bs.mie.2024.04.013}
}
Kostenlos starten →